Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | PF-06801591 |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | PF-06801591 | Phase Ib/II | Actionable | In Phase Ib/II trial, PF-06801591 (sasanlimab) therapy was well tolerated in patients with locally advanced or metastatic non-small cell lung cancer and resulted in an objective response rate (ORR) of 16.4% (11/67, 11 partial responses), disease control rate of 56.7% (38/67), median progression-free survival of 3.7 months, and median overall survival of 14.7 months, with an ORR of 36.4% (4/11) in patients with high CD274 (PD-L1) expression (>/=50%) (PMID: 37385154; NCT02573259). | 37385154 |
PubMed Id | Reference Title | Details |
---|---|---|
(37385154) | A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. | Full reference... |